Galena Biopharma acquires Mills Pharmaceuticals, LLC

PORTLAND, Ore.—Galena Biopharma, a biopharmaceutical company developing and commercializing targeted oncology treatments that address major unmet medical needs, has acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled-release formulation of anagrelide. Galena expects to pursue the expedited 505(b)(2) regulatory pathway to seek approval of GALE-401 for the treatment of essential thrombocythemia (ET). The company also believes GALE-401 meets the qualifications for orphan drug status and estimates peak market size for the drug of approximately $200 million in the U.S.

 

"This acquisition is an excellent fit for Galena's focused business strategy, adding another novel product to our pipeline which strengthens the depth and breadth of our hematology-oncology portfolio," said Mark J. Ahn, Ph.D., president and CEO of Galena. "ET is a serious condition in which current agents often have very debilitating side effects. We believe GALE-401 can enhance the therapeutic index for ET patients—reducing the side effects of anagrelide while maintaining efficacy for these patients. With established guidance from the FDA on the development process, we are excited to initiate a Phase 2 study in mid-2014."

 

One of four myeloproliferative disorders, essential thrombocythemia (ET) is an acquired disease of the bone marrow characterized by highly elevated platelet counts produced,by megakaryocytes and is associated with vascular complications, including increased risk of thrombosis and bleeding, and events such as heart attack and stroke. In some cases the disorder may be progressive, and rarely may evolve into acute myeloid leukemia or myelofibrosis. Anagrelide immediate release (IR) is currently one of two generic drugs approved to treat ET. However, a significant number of patients are unable to tolerate fully effective doses of anagrelide IR and either discontinue treatment or are reduced to a dose which is insufficient to achieve the target platelet level.

 

GALE-401 is expected to greatly decrease the adverse event rate relative to the approved product. The adverse events of IR anagrelide—nausea, diarrhea, abdominal pain, palpitations, tachycardia, headache—are tied to the peak concentration, or Cmax, and these side effects often limit dose escalation resulting in inadequate control of disease or discontinuation of therapy. Existing data strongly suggest reducing the Cmax while maintaining the overall exposure to the drug, or AUC (area under the curve), which reduces the rate of adverse events without compromising efficacy. GALE-401 significantly decreases the Cmax by up to 70 percent while preserving nearly 100 percent of the AUC.

 

This favorable pharmacokinetic profile for GALE-401 has been established in several Phase 1 studies enrolling an aggregate 86 healthy subjects. Across all studies, a dose dependent reduction in platelet count was observed, and importantly, the safety profile of GALE-401 was no different from placebo. It is anticipated that the dosing and tolerability advantages will potentially allow Galena to expand the market to treat both younger and elderly patient populations with ET who are currently undertreated.

 

Based on a regulatory meeting with the U.S. Food and Drug Administration (FDA), Galena believes a 505(b)(2) regulatory filing is an acceptable paradigm for approval of GALE-401, with the reference drug Agrylin(R) (anagrelide; Shire Pharmaceuticals). The Phase 1 program has provided the desired pharmacokinetic/pharmacodynamic (PK/PD) profile to enable the Phase 2 initiation. The FDA has also indicated that only a single Phase 3 trial is required for approval.

 

"Many physicians are not satisfied with currently available treatments for ET due to the fact that they cannot effectively lower and maintain platelet levels in many of their patients without unmanageable side effects. GALE-401 is designed to deliver anagrelide with controlled release over a longer period of time to take advantage of the known benefits of the drug, while reducing the adverse events to offer a better treatment option for patients," said Srdan Verstovsek, M.D., Ph.D., chief, Section for Myeloproliferative Neoplasms (MPNs), Department of Leukemia, director, Clinical Research Center for MPNs, the University of Texas MD Anderson Cancer Center.

 

Under the terms of the agreement, Galena made an up-front payment to Mills Pharmaceuticals' owners. Additionally, Mills Pharmaceuticals owners are eligible to receive one-time payments of up to 4,000,000 shares with the achievement of specified regulatory milestones. The owners are also eligible to receive $3 million upon FDA approval of a new drug application in respect to GALE-401. GALE-401 possesses a broad patent portfolio and provides intellectual property protection through at least 2029. Mills Pharmaceuticals is affiliated with Aceras Partners, a healthcare-focused investment firm that specializes in funding the development of novel medical innovations by collaborating with pharmaceutical companies, biotechnology companies, and research centers from around the world.. Roth Capital Partners acted as financial advisor to Galena in this transaction.

 

Essential thrombocythemia (ET) is an acquired disease of the bone marrow, characterized by highly elevated platelet counts, and is associated with vascular complications including increased risk of thrombosis and bleeding events such as heart attack and stroke. Galena believes ET meets the qualifications of an orphan drug with prevalence in the U.S. of approximately 80,000-100,000 and an annual incidence rate of about 8,000 new diagnoses each year, with similar rates in Europe. Initially, many patients are asymptomatic so the disease goes undiagnosed, but with increased standard blood testing, the diagnoses are increasing as well. Only about 75 percent of diagnosed patients currently receive therapeutic treatment.

 

Source: Galena Biopharma

 

 

http://www.acerasbio.com.